Please login or register to print this page.

News & Views

CLARITY trial looks at efficacy, safety and efficiency of catheter ablation of AF

Biosense Webster has announced that it has obtained its first Ethics Committee approval for the CLARITY study, comparing the 1-year efficacy, safety and efficiency of CARTO® 3 System-guided radiofrequency ablation using the NAVISTAR®

THERMOCOOL® Catheter versus fluoroscopy-guided radiofrequency ablation using the Pulmonary Vein Ablation Catheter® (PVAC®, Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation.

This prospective, multi-center, randomized (2:1), controlled, two-arm clinical study will enroll up to 350 patients at up to 15 sites throughout Europe and Canada. The 1-year efficacy results are expected to be available by Q2 2012, whereas the safety and efficiency data for both procedures will already be available by Q2 2011.

“The CLARITY trial is the first randomized trial comparing the efficacy and safety of these existing ablation strategies for atrial fibrillation. Given the growing epidemics of atrial fibrillation, the results of this landmark trial will guide optimal treatment in a large patient population” said Prof. Mattias Duytschaever, principal investigator of the CLARITY study.

The hypothesis of this trial is that treatment with the NAVISTAR® THERMOCOOL®  Catheter, with CARTO® 3 System guidance, will provide superior efficacy and safety for the treatment of paroxysmal atrial fibrillation vs. the PVAC® catheter, without decreasing the efficiency of the ablation procedure.

CARTO® 3 System is the third generation of the CARTO® electro-anatomical mapping system. CARTO® 3 System is built on the core magnetic based CARTO® proprietary technology, which has been recognized as the gold standard in its domain, with a special focus on increased performance, ease of use and EP lab efficiency.

The NAVISTAR® THERMOCOOL® Catheter, manufactured by Biosense Webster, Inc. is one of the most widely adopted catheter for the treatment of atrial fibrillation in Europe, and the only ablation catheter approved by the U.S. Food and Drug Administration for the treatment of drug refractory recurrent symptomatic paroxysmal AFib when used with CARTO® Navigation Systems.

Published on: April 20, 2010

Members Area

Log in or Register now.

SEARCH THE SITE

RSS FEED

Subscribe to our RSS feed
home

GET EXCLUSIVE UPDATES

Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.

RECENT COMMENTS

    None Found

ENDORSED BY

  • ArrhythmiaAlliance
  • Stars
  • Anticoagulation Europe
  • Atrial Fibrillation Association
 

You are not logged in

You need to be a member to print this page.
Sign up for free membership, or log in.

You are not logged in

You need to be a member to download PDF's.
Sign up for free membership, or log in.